Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer

NCT06849947 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

272

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer Metastatic

Interventions

DRUG: Ribociclib with fulvestrant
DRUG: Physician's choice treatments group

Sponsor

Yeon Hee Park